[{"id":"19899ca6-56d4-4952-beaa-c4745d820e14","acronym":"","url":"https://clinicaltrials.gov/study/NCT03131908","created_at":"2021-01-18T15:25:52.146Z","updated_at":"2025-02-25T13:12:18.989Z","phase":"Phase 1/2","brief_title":"Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss","source_id_and_acronym":"NCT03131908","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-13"},{"id":"64151ea0-5e4f-4551-a71f-36af8cc5de9e","acronym":"IPATential150","url":"https://clinicaltrials.gov/study/NCT03072238","created_at":"2021-01-17T17:45:45.867Z","updated_at":"2024-07-02T16:34:37.052Z","phase":"Phase 3","brief_title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03072238 - IPATential150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • ipatasertib (RG7440) • prednisone • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 1101","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/16/2020","primary_completion_date":" 03/16/2020","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2024-06-07"},{"id":"97b43e3f-fef1-4710-bf54-e72318c22ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439188","created_at":"2021-01-18T21:22:07.541Z","updated_at":"2024-07-02T16:35:05.160Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)","source_id_and_acronym":"NCT04439188","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-08"},{"id":"c658257f-75f4-4d06-aee3-2acd2eb60e2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01485861","created_at":"2021-01-17T17:57:48.754Z","updated_at":"2024-07-02T16:35:37.064Z","phase":"Phase 1/2","brief_title":"Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy","source_id_and_acronym":"NCT01485861","lead_sponsor":"Genentech, Inc.","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • ipatasertib (RG7440) • prednisone • apitolisib (GDC-0980)"],"overall_status":"Completed","enrollment":" Enrollment 298","initiation":"Initiation: 01/11/2012","start_date":" 01/11/2012","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-09-14"},{"id":"9d91071d-a117-4519-9680-9467f294f957","acronym":"","url":"https://clinicaltrials.gov/study/NCT01896531","created_at":"2021-01-18T08:30:44.148Z","updated_at":"2024-07-02T16:36:16.170Z","phase":"Phase 2","brief_title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT01896531","lead_sponsor":"Genentech, Inc.","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 08/14/2013","start_date":" 08/14/2013","primary_txt":" Primary completion: 06/03/2015","primary_completion_date":" 06/03/2015","study_txt":" Completion: 01/26/2021","study_completion_date":" 01/26/2021","last_update_posted":"2022-03-02"},{"id":"ea0c70bf-d79a-4a55-a1cf-881b61a43371","acronym":"TQBSP","url":"https://clinicaltrials.gov/study/NCT04690725","created_at":"2021-01-19T20:48:34.538Z","updated_at":"2024-07-02T16:36:36.671Z","phase":"Phase 1/2","brief_title":"TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss","source_id_and_acronym":"NCT04690725 - TQBSP","lead_sponsor":"Peking University People's Hospital","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3525"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-12-31"},{"id":"90762e7b-9b49-4cdc-9c55-def51a763cb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665687","created_at":"2021-01-19T20:43:35.488Z","updated_at":"2024-07-02T16:36:37.054Z","phase":"","brief_title":"Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients","source_id_and_acronym":"NCT04665687","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • HER-2 • PD-L1 • ALK • FGFR2 • PTEN","pipe":" | ","alterations":" PTEN loss","tags":["EGFR • HER-2 • PD-L1 • ALK • FGFR2 • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"],"overall_status":"Recruiting","enrollment":" Enrollment 1730","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-12-21"},{"id":"64dc377c-8fcd-432d-95e8-37fc6bb1ae8c","acronym":"PROSABI","url":"https://clinicaltrials.gov/study/NCT02787837","created_at":"2021-01-18T13:40:35.180Z","updated_at":"2024-07-02T16:36:50.956Z","phase":"","brief_title":"PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.","source_id_and_acronym":"NCT02787837 - PROSABI","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"e4b470a6-e3f3-473a-b3dd-c583115f597e","acronym":"PROSTAC","url":"https://clinicaltrials.gov/study/NCT02362620","created_at":"2021-01-18T11:14:49.607Z","updated_at":"2024-07-02T16:36:50.915Z","phase":"","brief_title":"PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.","source_id_and_acronym":"NCT02362620 - PROSTAC","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 402","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"c8f6f9a4-000e-4a71-bbdc-caffef6d382d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00311623","created_at":"2021-01-18T01:04:26.384Z","updated_at":"2024-07-02T16:37:02.562Z","phase":"Phase 1/2","brief_title":"Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer","source_id_and_acronym":"NCT00311623","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PTEN • CASP3","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 06/01/2010","study_completion_date":" 06/01/2010","last_update_posted":"2019-02-22"},{"id":"073d5921-74ce-462c-a8f3-c57f54b6c4a3","acronym":"RE-AKT","url":"https://clinicaltrials.gov/study/NCT02525068","created_at":"2021-01-18T12:12:22.490Z","updated_at":"2024-07-02T16:37:08.091Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC","source_id_and_acronym":"NCT02525068 - RE-AKT","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • Truqap (capivasertib)"],"overall_status":"Unknown status","enrollment":" Enrollment 136","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2018-08-08"}]